Navigation Links
How much is life worth? The $440 billion question
Date:7/3/2009

The decision to use expensive cancer therapies that typically produce only a relatively short extension of survival is a serious ethical dilemma in the U.S. that needs to be addressed by the oncology community, according to a commentary published online June 29 in the Journal of the National Cancer Institute.

Tito Fojo, M.D., Ph.D., of the Medical Oncology Branch, Center of Cancer Research at the National Cancer Institute, in Bethesda, Md., and Christine Grady, Ph.D., of the Department of Bioethics, the Clinical Center at the National Institutes of Health, tackle the controversy concerning the life-extending benefits of certain cancer drugs and the extent to which their cost should factor in deliberations.

The authors illustrate cost-benefit relationships for several cancer drugs, including cetuximab for treatment of non-small cell lung cancer, touted as "practice changing" and new standards of care by professional societies, including the American Society of Clinical Oncology.

They ask, "Is an additional 1.7 months [the additional overall survival for colorectal cancer patients treated with cetuximab] a benefit regardless of costs and side effects?"

According to Fojo and Grady, in the U.S., 18 weeks of cetuximab treatment for non-small cell lung cancer, which was found to extend life by 1.2 months, costs an average of $80,000, which translates into an expenditure of $800,000 to prolong the life of one patient by 1 year. At this rate, it would cost $440 billion annually, an amount 100 times NCI's budget, to extend the lives of 550,000 Americans who die of cancer annually by 1 year.

To address the issue, the commentators recommend that studies powered to detect a survival advantage of two months or less should test only interventions that can be marketed at a cost of less than $20,000 for a course of treatment.

Every life is of infinite value, the authors say, but spiraling costs of cancer care makes this dilemma inescapable.

"The current situation cannot continue. We cannot ignore the cumulative costs of the tests and treatments we recommend and prescribe. As the agents of change, professional societies, including their academic and practicing oncologist members, must lead the way," the authors write. "The time to start is now."


'/>"/>

Contact: Steve Graff
jncimedia@oxfordjournals.org
301-841-1285
Journal of the National Cancer Institute
Source:Eurekalert

Related biology technology :

1. Boston Scientific Amends Credit Facility and Prepays $1 Billion on Loan
2. Medco Announces Agreement to Acquire Diabetes Care Leader PolyMedica in Transaction Valued at $1.5 Billion
3. Biogenerics Will Save Billions, Says Hospira CEO
4. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
5. Wyeth Announces $5 Billion Share Repurchase Program; Declares Increase in Common Stock Dividend
6. Entry of Biogenerics and Decreasing Use of Amgens Epogen and Johnson & Johnsons Procrit Will Cause a $2.8 Billion Decline in the Drug Market for Chemotherapy-Induced Anemia by 2016
7. Surgical and Trauma Wound Care Market to Tie Up $7 Billion in Sales by 2011
8. Foamix Signs Term Sheet to Acquire License to Organo-Boron Antifungal Molecules - Will Target the $11 Billion Dollars Fungal Infection Market
9. Study by Leading Economist Identifies Potential for $378 Billion of Savings From Follow On Biologics
10. Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark.
11. Medco Issues $1.5 Billion of Senior Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... ... February 04, 2016 , ... Morf Media Inc ... an interactive FDA compliance training course, Writing Effective SOPs ... accredited interactive course on Morf Playbook—now conveniently available on smartphones and PCs--provides step ...
(Date:2/4/2016)... ... February 04, 2016 , ... ... and triple quad LC-MS, host live demos and poster sessions, and present on ... exhibition. The conference takes place March 6 to 10 at the Georgia World ...
(Date:2/4/2016)... JUNCTION, N.J. , Feb. 4, 2016 /PRNewswire/ ... care immunotherapy leader commercializing its flagship CytoSorb® blood ... cardiac surgery patients around the world, announced that ... will present at the Source Capital Group,s 2016 ... and update on the company.  ...
(Date:2/4/2016)... N.J. , Feb. 4, 2016 ContraVir ... focused on the development and commercialization of targeted antiviral ... CEO & Investor Conference 2016, to be held February ... Source Capital Group,s 2016 Disruptive Growth & Healthcare Conference, ... on February 10-11, 2016. James Sapirstein , ...
Breaking Biology Technology:
(Date:1/11/2016)... Synaptics Incorporated (NASDAQ: SYNA ), the ... its ClearPad ® TouchView ™ 4300 touch ... categories in the 8 th Annual Mobile Excellence ... The Synaptics ® TDDI solution enables faster time-to-market, ... devices, brighter displays and borderless designs. ...
(Date:1/8/2016)... Connecticut , January 8, 2016 ... m-commerce market and WorldVentures ® , a privately held ... and an Inc. 5000 fastest-growing company announced ... strategic investment of $2 million in Nxt-ID to develop ... based on Nxt-ID,s Wocket ® , a unique smart ...
(Date:1/7/2016)... 2016  A United States District Court in ... the country to interpret a biometric privacy statute in ... against the photo website Shutterfly brought by the law firm ... vs. SHUTTERFLY, INC.; and THISLIFE, INC ( N.D. ... violates the Illinois Biometric Privacy Act by collecting and ...
Breaking Biology News(10 mins):